Maze Therapeutics swaps Frazier stock for pre-funded warrants

Maze Therapeutics, Inc. disclosed in an 8-K filing that on October 15, 2026, it entered into an exchange agreement with Frazier Life Sciences Public Fund, L.P. and three affiliated Frazier entities. Under the agreement, Maze exchanged an aggregate of 2,776,007 shares of Maze's common stock held by the Frazier funds for pre-funded warrants to purchase an aggregate of 2,776,007 shares of common stock, with an exercise price of $0.001 per share.¹

Following the exchange, Maze's outstanding common stock as of October 16, 2026 was 53,931,889 shares.¹

The warrants carry restrictions on exercise. The exchange warrants may be exercised at any time after issuance, except that the Frazier funds cannot exercise them if doing so would result in beneficial ownership exceeding 9.99% of outstanding common stock, subject to certain exceptions.¹ Additionally, holders of the exchange warrants will not have the right to vote the underlying shares on any matter except as required by Delaware law.¹

The warrants were issued without registration. The exchange warrants will be issued without registration under the Securities Act of 1933, relying on the exemption contained in Section 3(a)(9) of that act.¹

The form of the pre-funded warrant was previously filed as an exhibit to an earlier Maze 8-K. The form of pre-funded warrant was incorporated by reference to Exhibit 4.1 of Maze Therapeutics' Current Report on Form 8-K filed with the Commission on April 22, 2026.¹ The exchange agreement itself was filed as Exhibit 10.1 to the current report. The filing was signed by Courtney Phillips, General Counsel and Corporate Secretary, on October 16, 2026.